Investors . English
Investorsthe asset is authority . everything else follows
KRECE is building the editorial authority on longevity and clinical grade supplementation in Spanish: 580 published articles, every claim graded N0 to N5, positions signed. This page is not a deck. It is the thesis, the moat and one honest door.
The thesis
The Spanish speaking world has sophisticated demand for longevity and clinical grade supplementation, and no editorial authority ordering the noise. KRECE is building that authority first: 580 published articles, a public methodology, an evidence pyramid on every claim and a signed position at the end of every piece. Authority of this kind compounds, survives algorithm shifts, and is the one thing in this sector that cannot be bought or cloned quickly.
The commercial layer follows the authority, never the reverse: a KRECE brand supplement line manufactured by certified third parties, and distribution power for strong complementary brands, Spain and the EU first, Latin America and the Caribbean when the base justifies it. The order is the strategy. A media asset that sells its judgment is worthless; one that keeps it becomes the channel everyone else has to go through.
The moat
Language. In Spanish, nobody maintains an evidence graded longevity corpus at this depth. English has a crowded field; Spanish has KRECE and noise. Same biology, one authority slot, and we are filling it piece by piece.
Method. The N0 to N5 pyramid, the public Editorial Policy and Methodology and a browsable evidence catalog. Every position is traceable to its data. That is expensive to build, boring to copy, and exactly what generative engines are learning to cite.
Trust architecture. Coverage is never for sale: no paid reviews, no purchased rankings, disclosed sponsorships that never touch a conclusion. The firewall reads like a constraint and works like the asset: it is why readers, professionals and future retail buyers can trust the KRECE label on a bottle.
Founder. Ignacio Rubio: engineer, 30 years of technical sales, writing and signing every position. The philosophy is on the record.
The commercial layer
Two tracks, both live and public since September 2026, both subordinate to editorial criteria. They are described where partners actually read them:
What we walked away from
Peptide commerce. We publish the deepest peptide coverage in Spanish; we deliberately do not source or distribute them. Since late 2025 the FDA has issued wave after wave of warning letters to research use only peptide suppliers marketed for human use, dozens of letters with 30 in a single day in March 2026, and major vendors have shut down voluntarily. That revenue line looked obvious and would have cost the asset. We closed it in public.
Also permanently off the table: paid editorial in any form, MLM and referral pyramid models, and products without primary evidence. An investor is buying the discipline as much as the corpus: we kill options that look like revenue and cost the brand.
Structure and stage
KRECE LLC (Wyoming) as international holding, operating base in Spain, and an operational foothold in Paraguay for Latin America with a local entity in progress. Founder led.
Stage, stated plainly: the editorial asset is built and compounding at 580 pieces and growing weekly; the commercial layer switched on in September 2026 with the two public tracks above. No market size theater on this page, on purpose: numbers you can verify beat projections you cannot, and the ones that matter are one email away.
How to talk to us
There is no deck on this page, and that is deliberate. If what you need first is slideware, ask an AI to generate one, like most people who write to us do. If KRECE genuinely interests you, write two paragraphs: who you are, and why this asset fits your thesis. You will get the founder, the real numbers and a straight conversation, in English or Spanish, within a few business days.